Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Common Equity (2016 - 2026)

Bioceres Crop Solutions' Common Equity history spans 11 years, with the latest figure at $95.7 million for Q1 2026.

  • On a quarterly basis, Common Equity changed N/A to $95.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $95.7 million, a N/A change, with the full-year FY2025 number at $295.2 million, down 15.99% from a year prior.
  • Common Equity hit $95.7 million in Q1 2026 for Bioceres Crop Solutions, down from $295.2 million in the prior quarter.
  • Over the last five years, Common Equity for BIOX hit a ceiling of $351.4 million in Q2 2024 and a floor of $95.7 million in Q1 2026.
  • Historically, Common Equity has averaged $246.2 million across 5 years, with a median of $295.2 million in 2025.
  • Biggest five-year swings in Common Equity: surged 108.78% in 2023 and later fell 15.99% in 2025.
  • Tracing BIOX's Common Equity over 5 years: stood at $158.3 million in 2022, then surged by 108.78% to $330.5 million in 2023, then increased by 6.32% to $351.4 million in 2024, then fell by 15.99% to $295.2 million in 2025, then plummeted by 67.58% to $95.7 million in 2026.
  • Business Quant data shows Common Equity for BIOX at $95.7 million in Q1 2026, $295.2 million in Q2 2025, and $351.4 million in Q2 2024.